April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Life Expectancy of Patients with Intraocular Lymphoma after Peripheral Blood Stem Cell Transplantation
Author Affiliations & Notes
  • Manfred Zierhut
    Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • Tarek Bayyoud
    Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • Bianka Sobolewska
    Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • Christoph M E Deuter
    Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • Footnotes
    Commercial Relationships Manfred Zierhut, None; Tarek Bayyoud, None; Bianka Sobolewska, None; Christoph Deuter, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3102. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Manfred Zierhut, Tarek Bayyoud, Bianka Sobolewska, Christoph M E Deuter; Life Expectancy of Patients with Intraocular Lymphoma after Peripheral Blood Stem Cell Transplantation. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3102.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Primary intraocular lymphoma (PIOL) is the ocular disorder with the shortest 5-year survival time. It is mostly a diffuse large B-cell non-Hodgkin lymphoma. Up to 80% are associated with or will develop CNS-lymphoma. This is the reason for treating even isolated ocular disease systemically. Current treatment involves mainly intravenous high dose methotrexate (MTX) for PIOL. Peripheral blood stem cell transplantation (PBSCT) has been shown to be very effective for primary CNS lymphoma.

Methods: Retrospective observational study of 5 patients with intraocular lymphoma without (n=2) or with CNS involvement (n=3). All patients had standardized clinical and ophthalmological assessments. All patients received PBSCT in addition to high dose intravenous MTX. Three of these patients received additional chemotherapeutics and 1 patient radiation therapy.

Results: Five patients (3 female and 2 male) with intraocular lymphoma were included in this study. The mean age at the initial presentation was 55.2 years (range: 40-74 years). The mean time of survival, starting with the initial symptoms, was 77.2 months (range: 25-136 months). All patients showed complete response of their intraocular and CNS-lymphoma. Today all patients are alive without any signs of relapses.

Conclusions: Treatment of intraocular lymphoma with PBSCT in addition to chemotherapeutics resulted in all patients in complete remission and long survival time.

Keywords: 744 tumors • 745 uvea • 555 immunomodulation/immunoregulation  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×